v3.25.2
Segment information
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment information

8. Segment information

 

The CODM has been identified as the CEO. The Company’s CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it has a single operating segment composed of the consolidated financial results of Bone Biologics Corporation.

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

 

   2025   2024 
   Six months ended
June 30,
 
   2025   2024 
Revenue  $-   $- 
           
Less:          
Research and development   615,186    596,067 
Salaries   250,000    250,000 
Insurance   143,193    199,585 
Stock-based compensation   123,504    70,124 
Operating expenses   652,423    549,330 
Other income   (26,695)   (15,403)
Net loss  $(1,757,611)  $(1,649,703)